ArticleHarm reduction journal2025
Doctors' and pharmacists' perspectives on the clinical use of medicinal Cannabis: a cross-sectional study.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Attitudes and expectations of primary care physicians regarding recreational cannabis legalization in Germany: a pre-implementation survey.Journal of cannabis research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the first EU country to enact laws regulating the non-medical use of cannabis and with established legislation for the cultivation and production of cannabis for medical purposes and scientific research, Malta is at the forefront of cannabis regulation and research initiatives. Despite this context, healthcare professionals' attitudes, beliefs, and knowledge regarding medicinal cannabis remain variable. We assess these constructs and examine perceived barriers to clinical integration.
methodsA cross-sectional survey was distributed to doctors and pharmacists across Malta (n = 198). Data analysis included independent samples t-tests, Pearson correlation analyses, and hierarchical regression to examine demographic influences, professional comparisons, and predictors of prescription attitudes.
resultsMost professionals acknowledged medicinal cannabis's therapeutic benefits but exhibited notable hesitancy in clinical practice, largely due to insufficient formal guidelines and inadequate education. No significant gender differences were observed, and only a weak correlation emerged between age and attitudes among male doctors. The strongest predictor of willingness to prescribe medicinal cannabis was doctors' attitudes, outweighing formal education or knowledge.
conclusionsDespite broad acknowledgment of potential therapeutic benefits, Maltese healthcare professionals remain cautious due to insufficient training and unclear guidelines. Enhancing evidence-based education and providing clear prescribing frameworks may significantly boost clinicians' confidence and willingness to integrate medicinal cannabis into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.